Peptide-receptor radionuclide therapy with radiolabelled somatostatin analogues is a successful new treatment modality for patients with neuroendocrine tumours. Usually, 90yttrium (90Y)-coupled or 177lutetium (177Lu)-coupled somatostatin analogues are used, but a new study claims that combining the two radiopharmaceuticals results in improved overall survival.